Canaccord Genuity Downgrades DICE Therapeutics to Hold, Lowers Price Target to $48
Portfolio Pulse from richadhand@benzinga.com
Canaccord Genuity analyst Edward Nash downgrades DICE Therapeutics (NASDAQ:DICE) from Buy to Hold and lowers the price target from $71 to $48.
June 20, 2023 | 3:48 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
DICE Therapeutics downgraded to Hold by Canaccord Genuity, with a lowered price target of $48.
The downgrade from Buy to Hold and the lowering of the price target from $71 to $48 by Canaccord Genuity analyst Edward Nash indicates a less optimistic outlook for DICE Therapeutics. This could lead to a negative short-term impact on the stock price as investors may adjust their positions based on the new rating and price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100